CAR-T cell therapy + chidamide + PD-1 inhibitor

This is a combination immunotherapy regimen consisting of CD19-directed Chimeric Antigen Receptor T (CAR-T) cell therapy followed by maintenance treatment with chidamide and a Programmed Cell Death Protein 1 (PD-1) inhibitor. Developed for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), the regimen utilizes chidamide (tucidinostat), an oral selective histone deacetylase (HDAC) inhibitor, to modulate the tumor microenvironment and upregulate target antigens, thereby enhancing CAR-T cell efficacy. The addition of a PD-1 inhibitor (such as sintilimab) aims to prevent T-cell exhaustion and maintain the cytotoxic activity of the infused CAR-T cells. Clinical studies led by Daihong Liu have demonstrated that this maintenance strategy can significantly improve progression-free and overall survival in high-risk aggressive B-cell lymphoma patients.

Other names

Chidamide and PD-1 Blockade Maintenance After CAR-T for B-cell Lymphomatucidinostat + sintilimab + CD19-directed CAR-T cell therapy